To determine the outcome of high-dose therapy with autologous hematopoietic stem cell transplantation (HSCT) in patients with primary systemic amyloidosis reported to the Center for International Blood and Marrow Transplant Research (CIBMTR).
High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation for Patients With Primary

PATIENTS AND METHODS:
A total of 107 recipients of autologous HSCT for amyloidosis from 48 transplantation centers were reported to the CIBMTR between 1995 and 2001. Hematologic and organ responses were assessed at 100 days and 1 year. Transplantation-related mortality (TRM) was assessed at day 30 after HSCT. A multivariate analysis assessed factors that influenced overall survival.
RESULTS: Improvement at day 100 was seen in 1 or more amyloidosis-affected sites (bone marrow, kidney, liver, and/or heart) in 28 (36%) of 77 patients; the 1-year responses included complete response (16%), partial response (16%), stable disease (31%), and disease progression (10%). With a median follow-up of 30 months, the 1-and 3-year survival rates were 66% (95% confidence interval [CI], 56%-75%) and 56% (95% CI, 45%-66%), respectively. The day 30 TRM was 18% (95% CI, 11%-26%). In the multivariate analysis, only the year of transplantation (patients who most recently underwent transplantation) was associated with post-HSCT survival (P=.02).
CONCLUSION:
In this multi-institutional CIBMTR study, the 3-year survival rate was comparable to single-center results, with patients who more recently underwent transplantation faring better. Of note, the TRM was higher than that reported by single centers, which may reflect differences in patient selection and/or experience in treating this challenging disease. We hope that a better understanding of the recently recognized prognostic factors and more stringent patient selection will result in lower TRM and improved survival.
Mayo Clin Proc. 2006;81(7):880-888 CI = confidence interval; CIBMTR = Center for International Blood and Marrow Transplant Research; HSCT = hematopoietic stem cell transplantation; KPS = Karnofsky performance score; TRM = transplantationrelated mortality P rimary systemic amyloidosis is an uncommon plasma cell dyscrasia, with approximately 2500 cases diagnosed yearly in North America. In this disease, monoclonal immunoglobulin light chains are produced by malignant plasma cells, resulting in amyloid fibril deposition in vital organs, leading to progressive, fatal multisystem failure. The median survival for treated patients is approximately 18 months compared with 12 months for untreated patients; the median survival for patients with symptomatic cardiac involvement is only 6 months. 1, 2 Conventional therapy for primary systemic amyloidosis has historically been with melphalan and prednisone.
3 Response rates are observed in 20% to 35% of patients, which results in a modest increase in survival. More recently, dexamethasone, dexamethasone combined with interferon, thalidomideor anthracycline-based regimens, and other novel therapies have been studied with comparable response rates. [4] [5] [6] [7] [8] [9] With the favorable outcomes observed with high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT) in multiple myeloma, pilot trials to test this approach in primary systemic amyloidosis were pursued. [10] [11] [12] [13] [14] [15] These pilot trials, which predominantly used high-dose melphalan, again based on the experience in multiple myeloma, showed encouraging results: the hematologic response rate was approximately 60%; organ response rates were also observed but at a lower rate. Unfortunately, these early pilot trials were associated with a high transplantation-related mortality (TRM) of 15% to 25%. In patients with AL cardiomyopathy, mortality approached 65%. 10, 12 More recently, clinical trials conducted with more stringent patient selection criteria have reported a lower TRM of 10% to 15%. [16] [17] [18] [19] [20] [21] [22] [23] Since primary systemic amyloidosis is a rare entity, only a few academic programs have a specific focus on the treatment of this disease. In the United States, the primary research centers are the Mayo Clinic in Rochester, Minn, and Boston University in Boston, Mass. Most patients with primary systemic amyloidosis, however, are treated outside these 2 centers. Although the outcomes of HSCT in primary systemic amyloidosis at the Mayo Clinic and Boston University are impressive, it is important to determine whether comparable outcomes can be reproduced in the general academic community. To this end, in 2001, the Center for International Blood and Marrow Transplant Research (CIBMTR) initiated a study of autologous HSCT outcomes in patients with primary systemic amyloidosis.
PATIENTS AND METHODS
DATA SOURCES
The CIBMTR is a research affiliation of the International Bone Marrow Transplant Registry, the Autologous Blood and Marrow Transplant Registry, and the National Marrow Donor Program that comprises a voluntary working group of more than 450 transplantation centers worldwide that contribute detailed data on consecutive allogeneic and autologous HSCTs to a Statistical Center at the Health Policy Institute of the Medical College of Wisconsin in Milwaukee or the National Marrow Donor Program Coordinating Center in Minneapolis, Minn. Participating centers are required to report all transplantations consecutively; compliance is monitored by on-site audits. Patients are followed up longitudinally, with yearly follow-up. Computerized checks for errors, physicians' review of submitted data, and on-site audits of participating centers ensure data quality. Observational studies conducted by the CIBMTR are performed with a waiver of informed consent and in compliance with Health Insurance Portability and Accountability Act regulations as determined by the institutional review board and the privacy officer of the Medical College of Wisconsin.
The CIBMTR collects data at 2 levels: registration and research. Registration data include disease type, age, sex, pretransplantation disease stage and chemotherapy responsiveness, date of diagnosis, graft type (bone marrow-and/ or blood-derived stem cells), high-dose conditioning regimen, posttransplantation disease progression and survival, development of a new malignancy, and cause of death. Requests for data on progression or death for registered patients are made at 6-month intervals. All CIBMTR teams contribute registration data. Research data are collected on a subset of registered patients selected by using a weighted randomization scheme and include detailed disease and pretransplantation and posttransplantation clinical information.
PATIENTS
Three hundred four patients were registered as having undergone autologous HSCT for primary systemic amyloidosis between 1995 and 2001. Of these 304 patients, comprehensive patient, disease, and transplant characteristics were available for 107 patients (35%). All patients included in the study were determined to have amyloidosis based on tissue biopsy findings. The definitions of organ involvement are as follows: renal, positive biopsy result or total urinary protein excretion greater than 3.5 g/24 h; hepatic, positive liver biopsy result or hepatomegaly (liver >12 cm); and cardiac, positive cardiac biopsy result, interventricular septal wall thickness greater than 15 mm, left ventricular ejection fraction of 40% or less, or New York Heart Association cardiac dysfunction class II to IV. The number of transplantations per center were as follows: 25 centers performed 1 transplantation only, 8 centers performed 2 transplantations, 7 centers performed 3 transplantations, 2 centers performed 5 transplantations, and 1 center performed 15 transplantations. No patients from Boston University or the Mayo Clinic were included in this study. Patient, disease, and transplant characteristics and overall survival of those with or without comprehensive data were similar. Eligible cases came from 48 reporting centers. Median follow-up of survivors was 30 months (range, 3-82 months).
END POINTS
At the time of this analysis, there were no universally accepted response criteria for amyloidosis. The response criteria for this study were defined as follows. A partial hematologic response was defined as a more than 50% decrease in urine and/or serum paraprotein levels, and a complete hematologic remission was defined as a negative urine and/or serum protein electrophoresis result. An organ response was defined as either improvement or lack of improvement in 3 organ systems: renal, hepatic, and cardiac. The determination of improvement was determined by the reporting center and not based on specified objective criteria. Recently, a uniform system was proposed at the 10th International Amyloidosis Symposium in April 2004. These criteria were subsequently presented at the December 2004 American Society of Hematology meeting. 24 Because of limitations inherent in the collection of registry data, it is not possible to retrospectively apply these criteria to the existing data set. Transplantation-related mortality was defined as all causes of death within 30 days after transplantation.
STATISTICAL ANALYSES
Estimates of overall survival were calculated using the Kaplan-Meier estimator, with SE estimated by the Greenwood formula. Ninety-five percent confidence intervals (CIs) were calculated using log-transformed intervals. Potential prognostic factors for survival were evaluated in a multivariate analysis using Cox proportional hazards regression. 25 The variables considered in the multivariate analysis were age at transplantation, sex, Karnofsky performance status (KPS) before transplantation (≤80% vs >80%), prior chemotherapy (no treatment vs melphalan with or without other therapy vs other chemotherapy vs other single agent), lines of therapy (≤1 vs >1), organ involvement at anytime before transplantation (≤1 vs >1 organ), cardiac involvement at anytime before transplantation (no vs yes), time from diagnosis to transplantation, conditioning regimen (melphalan alone vs others), and year of transplantation (1995-1997 vs 1998-1999 vs 2000-2001) . All computations were made using the procedure PHREG in the statistical package SAS, version 8 (SAS Institute Inc, Cary, NC). Forward stepwise variable selection at a .10 significance level was used to identify covariates associated with the main outcome. In the model, the assumption of proportional hazards was tested for each variable using a time-dependent covariate and graphic methods. All variables considered in the multivariate analysis satisfied the proportionality assumption. The final multivariate model was built using a forward stepwise model selection approach. Factors significant at a P=.05 level were kept in the final model. Examination for center effects used a random effects or frailty model. 26 We found no evidence of correlation between center and any of the outcomes. All P values are 2-sided.
RESULTS
PATIENT CHARACTERISTICS
The median patient age was 55 years (range, 31-71 years), with a male-female ratio of 60:40. All patients had a biopsy-confirmed diagnosis of primary systemic amyloidosis. The paraprotein isotypes were IgG (36 (Table 1) .
ORGAN INVOLVEMENT
The kidney was the most commonly reported involved organ, with urinary protein levels that exceeded 200 mg/24 h observed in 57 (93%) of 61 evaluated patients. Forty-four (72%) of 61 evaluated patients had nephrotic syndrome range proteinuria (protein >3 g/24h) and 37 (41%) of 90 had hypoalbuminemia. Approximately one third had an elevated serum creatinine level; 31 (29%) of 106 had creatinine levels greater than 2 mg/dL. Although not part of our definition of hepatic involvement, approximately one third (35/99) had elevated serum alkaline phosphatase levels greater than 1.5 times the institutional upper limit of normal, a marker that has been reported as consistent with hepatic involvement. Peripheral neuropathy was reported in one fourth of the patients. Cardiac involvement was documented by biopsy in 28 (26%) of 106 patients; subjective symptoms were reported in 34 (45%) of 76 patients (New York Heart Association class ≥II).
Most patients had only single organ involvement, whereas 35 (33%) of 107 had 2 or more organs involved; however, 16 (15%) of 107 did not have organ (heart, kidney, liver) involvement as per the definition given in the "Patients and Methods" section. Some of these patients had evidence suggestive of early involvement, such as a urinary protein level less than 3.5 g/24 h or an alkaline phosphatase level more than 1.5 times normal but no hepatomegaly and no liver biopsy.
PRIOR THERAPY
Approximately one third of patients had received no therapy before HSCT. Of those patients who received prior therapies, melphalan-based regimens were the most commonly used. Three fourths of the patients were minimally treated: 37 (35%) of 105 with no prior therapy and 42 (40%) of 105 with one prior treatment regimen. One fourth of the patients had 2 or more lines of prior therapy. The median time from diagnosis to transplantation was 6 months (range, 1-178 months), and the time from first treatment to transplantation was within 6 months in 76 (75%) of 102 patients. Seventeen (17%) of 102 patients had 6 to 12 months of prior therapy, and only 9 (9%) of 102 had more than 1 year of prior treatment. . Six patients were enrolled in tandem autologous transplantation protocols; 3 additional patients underwent tandem transplantations.
PREPARATIVE REGIMENS
RESPONSE
Responses at day 100 were seen in at least one organ system (hematologic, renal, hepatic, and/or cardiac) in 28 (36%) of the 77 patients with organ-specific data available.
Since response to therapy in patients with primary systemic amyloidosis may occur during a prolonged period, sometimes exceeding a year, response was evaluated 1 year after HSCT. 15 With regard to hematologic response, 34 (32%) of 107 patients had an objective response to transplantation equally divided between complete response (17 [16%] ) and partial response (17 [16%] ); 33 (31%) had stable disease, and 11 (10%) had progressive disease. The TRM was 27% (29/107 patients). Five of the 6 patients who had enrolled in a tandem transplantation protocol completed both transplantations. Three additional patients subsequently underwent tandem transplantations. The 1-year responses for these 9 patients were as follows: 3 with partial responses, 3 
OVERALL SURVIVAL
Overall survival after transplantation is shown in Figure 1 . The 1-year survival rate was 66% (95% CI, 56%-75%) and the 3-year survival rate was 56% (95% CI, 45%-66%) for the 107 patients. One-year survival rates in patients based on pretransplantation organ involvement (cardiac, renal, hepatic) were 72% (95% CI, 61%-82%) if 0 or 1 organ was involved and 54% (95% CI, 38%-70%) if 2 or more organs were involved ( (Figure 2) . Patient, disease, and treatment characteristics of the patients in the 2 groups based on year of transplantation were similar. Improvement of transplantation results over time was confirmed in the multivariate analysis of prognostic factors.
CAUSES OF DEATH
Nineteen patients (18%; 95% CI, 11%-26%) died of infection or organ failure within 30 days of transplantation. Cardiac failure was the most commonly reported organ-specific cause of death, occurring in 7 (37%) of 19 patients: 3 deaths occurred in patients with known cardiac involvement before transplantation, and 4 deaths occurred in patients without known cardiac involvement before transplantation. An additional 26 patients died beyond 30 days after transplantation due to disease progression (n=18) or other causes (n=8). Of these, 3 deaths from transplantation-related toxic effects (acute respiratory distress syndrome, interstitial pneumonitis, and infection) occurred between day 30 and day 100 after transplantation. 
PROGNOSTIC FACTORS
In univariate analysis, neither the number of organs involved nor the presence or absence of any 1 of the 3 organ systems evaluated (renal, hepatic, and cardiac) was predictive of overall survival (Table 2) . In multivariate analyses, the year of transplantation was the only statistically significant predictor of survival among patient-, disease-, or transplant-related variables (P=.02). 
DISCUSSION
Primary systemic amyloidosis is an uncommon plasma cell dyscrasia. The median survival for treated patients is approximately 18 months. 1, 2 Marginal improvement has occurred in the treatment of this disease during the past 20 years: melphalan and/or corticosteroid-based regimens remain the mainstay of treatment.
1-3,5-7 Some newer agents, such as thalidomide, which have proven efficacy in multiple myeloma, are still in pilot trials in primary systemic amyloidosis. 8, 9 In myeloma, these agents are reasonably well tolerated. However, most studies report that adverse effects from thalidomide are greater than those observed in myeloma. Whether lower doses, which are better tolerated, are sufficient for disease control in primary systemic amyloidosis is unclear. The use of monoclonal antibodies is provocative but is still in the early stages of clinical development. 27 During the past 10 years, evidence has been mounting that high-dose therapy with autologous HSCT is efficacious in controlling the malignant plasma cell clone present in patients with primary systemic amyloidosis. [16] [17] [18] [19] [20] [21] [22] [23] Reduction and/or elimination of the offending light chain paraprotein production and subsequent tissue infiltration may allow for improvement in end-organ function. [28] [29] [30] This ultimately translates to improve quality of life to a level that is not achieved with conventional therapy. 31 The initial efforts in high-dose therapy with HSCT in primary systemic amyloidosis were associated with high TRM, particularly for patients with cardiac amyloidosis and those with 2 or more organs involved. [10] [11] [12] The favorable results observed in these pilot studies have been considered by some to reflect in part patient selection bias. 14, 17 However, a case-control study has demonstrated the superiority of HSCT to conventional therapy. 32 A trial comparing HSCT to conventional therapy is currently being evaluated in a French phase 3 study.
The current study reports the outcomes in 107 patients with primary systemic amyloidosis undergoing HSCT from 48 centers, with only 3 centers contributing 5 or more patients. Because of the nature of a registry analysis, patient details and the response criteria are less stringent than those reported by single institutions or cooperative groups. The recent approval of uniform response criteria by the attendees of the 10th International Amyloidosis Symposium will provide consistent guidelines and assist in analysis of future studies, but these could not be retrospectively applied for this analysis. 24 Despite the lack of more stringent response criteria in this study, the 3-year overall observed survival is comparable to other reports from single institutions and cooperative groups ( Table 3) . The CIBMTR TRM at 30 days was higher (18%) than that reported by single institutions and cooperative groups. This finding may be explained by the absence of standardized eligibility criteria and treatment regimens from the various transplantation centers that may allow for higher-risk patients. Alternatively, the higher mortality may be a factor of inexperience in caring for these patients who often have multisystem compromise in contrast to patients with multiple myeloma, although no center-specific effect was identified in multivariate analysis. Even at transplantation centers experienced in the care of patients with primary systemic amyloidosis, the TRM for such patients undergoing HSCT approaches 10% to 15% compared with 1% to 2% for those with multiple myeloma. However, in multivariate analysis, patients who have more recently undergone transplantation had a superior outcome. This finding may reflect improved patient selection and/or increased experience in caring for patients with primary systemic amyloidosis along with improvements in supportive care during the past 10 years. In contrast to most other reports, neither cardiac involvement nor multiple organ involvement was predictive of overall survival in the current study. This may be a feature of the sample size in this study. However, of note, the Mayo Clinic experience did not observe a relationship between cardiac involvement by conventional assessment and overall survival. 15 This finding may also reflect the nature of studies conducted using an observational database that reports activities of member centers without dictating practices. Specifically, not all patients were systematically evaluated in the same manner for organ involvement before or after transplantation, and some patients may potentially have had organ involvement that was not characterized by the transplantation program.
To improve transplantation outcomes in primary systemic amyloidosis, it is necessary to address disease-related and treatment-related factors. Regarding disease-related factors, we now have a better understanding of primary systemic amyloidosis-associated prognostic factors: pro-brain natriuretic peptide, cardiac troponin, β 2 -microglobulin, and the number of organs involved. [21] [22] [23] 33 This information should be incorporated into the development of treatment strategies with more stringent patient selection criteria and risk-directed therapy. 16, 18, 22 Ultimately, this should result in lower TRM and improved survival. Future studies should incorporate these biologic prognostic factors and evaluate their value in HSCT. To maximize the knowledge gained from performing transplantations in patients with primary systemic amyloidosis and to use that information to design future prospective trials or to make treatment decisions for patients not eligible for clinical trials, centers must commit to systematically evaluating patients with primary systemic amyloidosis before and after transplantation for potential prognostic factors and organ involvement in such a way that the data can be pooled for analysis between centers. Ideally, centers should share their experience by reporting their data to national and multinational cooperative transplantation registries, such as the European Group for Blood and Marrow Transplantation and the CIBMTR because they provide a different perspective from that of the disease-focused expert center.
Transplantation outcomes should improve with better patient selection based on prognostic factors and potentially the use of comorbidity scores, as has been introduced in allogeneic transplantation studies. 34 Morbidity and mortality may also be improved through the use of a more tolerable transplantation regimen, such as a lower dose of melphalan. Unfortunately, lowering the dose of melphalan to reduce toxic effects has resulted in less pronounced response rates in some studies 22 but marginally so in other studies. 16 Another approach would be to administer melphalan in combination with a cytoprotectant agent such as amifostine or keratinocyte growth factor (palifermin). In myeloma, it has been demonstrated that amifostine as a 35 In this regard, the Eastern Cooperative Oncology Group has initiated a phase 1/2 study of dose-escalating melphalan with amifostine as a cytoprotectant. Palifermin was recently shown to reduce mucositis in patients undergoing radiation-based autologous HSCT. 36 Furthermore, if the transplantation-related morbidity and mortality can be adequately reduced, it may be possible to safely administer multiple cycles of doseintensive therapy with HSCT, 37, 38 as has been shown to be effective in multiple myeloma. 39 Finally, although the median overall survival with HSCT for primary systemic amyloidosis approaches 4 years in our study and 5 years in other studies, there does not appear to be a plateau of survival curves. 15, 16 The observation that a graft-vs-myeloma effect afforded by alloreactive T lymphocytes can result in long-term disease control in some patients with myeloma undergoing allogeneic transplantation 40, 41 may be predictive of a similar outcome in patients with primary systemic amyloidosis. The use of allogeneic transplantation for primary systemic amyloidosis, particularly with reduced-intensity conditioning regimens, has just started to be evaluated in pilot studies. 42, 43 These transplantations should be performed only within well-designed clinical trials at centers with expertise in the management of transplantation-related complications, such as graft-vs-host disease. All patients with primary systemic amyloidosis should be considered for clinical trials and may benefit by referral for evaluation to programs that specialize in the study and care of these patients.
CONCLUSION
In this multi-institutional CIBMTR study, the 3-year survival was comparable to single-center results, with patients who had more recently undergone transplantations faring better. Of note, the TRM was higher than that reported by single centers, which may reflect differences in patient selection and/or experience in treating this challenging disease. We hope that a better understanding of the recently recognized prognostic factors and more stringent patient selection will result in lower TRM and improved survival.
